LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY

被引：1
|
作者：
Mcinnes, I. [1 ]
Kato, K. [2 ]
Magrey, M. [3 ]
Merola, J. F. [4 ,5 ]
Kishimoto, M. [6 ]
Haaland, D. [7 ,8 ]
Chen, L. [2 ]
Duan, Y. [2 ]
Liu, J. [2 ]
Lippe, R. [9 ]
Wung, P. [2 ]
机构：
[1] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland
[2] AbbVie Inc, Immunol, N Chicago, IL USA
[3] Case Western Reserve Univ, Cleveland, OH 44106 USA
[4] Brigham & Womens Hosp, Boston, MA 02115 USA
[5] Harvard Med Sch, Dermatol & Rheumatol, Boston, MA 02115 USA
[6] Kyoto Univ, Sch Med, Dept Nephrol & Rheumatol, Tokyo, Japan
[7] McMaster Univ, Hamilton, ON, Canada
[8] Waterside Clin, Rheumatol & Clin Immunol Allergy, Barrie, ON, Canada
[9] AbbVie Deutschland GmbH Co KG, Immunol, Wiesbaden, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.799
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0081
引用
收藏
页码：260 / 261
页数：2
相关论文
共 50 条
  • [21] Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
    McInnes, Iain B.
    Kato, Koji
    Magrey, Marina
    Merola, Joseph F.
    Kishimoto, Mitsumasa
    Pacheco-Tena, Cesar
    Haaland, Derek
    Chen, Liang
    Duan, Yuanyuan
    Zueger, Patrick
    Liu, John
    Lippe, Ralph
    Pangan, Aileen L.
    Behrens, Franck
    RMD OPEN, 2021, 7 (03):
  • [22] Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
    Mease, Philip J.
    Merola, Joseph F.
    Tanaka, Yoshiya
    Gossec, Laure
    Mcinnes, Iain B.
    Ritchlin, Christopher T.
    Landewe, Robert B. M.
    Asahina, Akihiko
    Ink, Barbara
    Heinrichs, Andrea
    Bajracharya, Rajan
    Shende, Vishvesh
    Coarse, Jason
    Coates, Laura C.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1363 - 1382
  • [23] Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
    Strand, Vibeke
    Mease, Philip J.
    Soriano, Enrique R.
    Kishimoto, Mitsumasa
    Salvarani, Carlo
    Saffore, Christopher D.
    Zueger, Patrick
    McDearmon-Blondell, Erin
    Kato, Koji
    Gladman, Dafna D.
    RHEUMATOLOGY AND THERAPY, 2021, 8 (04) : 1789 - 1808
  • [24] Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
    Fleischmann, Roy
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles G.
    Durez, Patrick
    Tanaka, Yoshiya
    Swierkot, Jerzy
    Khan, Nasser
    Bu, Xianwei
    Li, Yihan
    Song, In-Ho
    RMD OPEN, 2022, 8 (01):
  • [25] Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
    Vibeke Strand
    Philip J. Mease
    Enrique R. Soriano
    Mitsumasa Kishimoto
    Carlo Salvarani
    Christopher D. Saffore
    Patrick Zueger
    Erin McDearmon-Blondell
    Koji Kato
    Dafna D. Gladman
    Rheumatology and Therapy, 2021, 8 : 1789 - 1808
  • [26] Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials
    Mease, Philip
    Kavanaugh, Arthur
    Gladman, Dafna
    FitzGerald, Oliver
    Soriano, Enrique R.
    Nash, Peter
    Feng, Dai
    Lertratanakul, Apinya
    Douglas, Kevin
    Lippe, Ralph
    Gossec, Laure
    RHEUMATOLOGY AND THERAPY, 2022, 9 (04) : 1181 - 1191
  • [27] UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY
    Mease, P. J.
    Lertratanakul, A.
    Papp, K.
    Van den Bosch, F.
    Tsuji, S.
    Dokoupilova, E.
    Keiserman, M.
    Bu, X.
    Chen, L.
    Mccaskill, R.
    Zueger, P.
    Mcdearmon-Blondell, E.
    Pangan, A.
    Tillett, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 312 - 314
  • [28] Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials
    Philip Mease
    Arthur Kavanaugh
    Dafna Gladman
    Oliver FitzGerald
    Enrique R. Soriano
    Peter Nash
    Dai Feng
    Apinya Lertratanakul
    Kevin Douglas
    Ralph Lippe
    Laure Gossec
    Rheumatology and Therapy, 2022, 9 : 1181 - 1191
  • [29] Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
    Mease, Philip J.
    Assad, Rodrigo Luppino
    Tsuji, Shigeyoshi
    Richette, Pascal
    Setty, Arathi
    McDearmon-Blondell, Erin
    Gao, Tianming
    Ciecinski, Sandra
    Van den Bosch, Filip
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4258 - 4261
  • [30] Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study
    Mclnnes, Lain B.
    Mease, Philip J.
    Kivitz, Alan J.
    Nash, Peter
    Rahman, Proton
    Rech, Jurgen
    Conaghan, Philip G.
    Kirkham, Bruce
    Navarra, Sandra
    Belsare, Ashwini D.
    Delicha, Eumoprhia M.
    Pricop, Luminita
    LANCET RHEUMATOLOGY, 2020, 2 (04): : E227 - E235
12345